Skip to main content
Log in

Is Repeat Resection for Recurrent Intrahepatic Cholangiocarcinoma Warranted? Outcomes of an International Analysis

  • Hepatobiliary Tumors
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Recurrence of intrahepatic cholangiocarcinoma (ICC) after liver resection (LR) remains high, and optimal therapy for recurrent ICC is challenging. Herein, we assess the outcomes of patients undergoing repeat resection for recurrent ICC in a large, international multicenter cohort.

Patients and Methods

Outcomes of adults from six large hepatobiliary centers in North America, Europe, and Asia with recurrent ICC following primary LR between 2001 and 2015 were analyzed. Cox models determined predictors of post-recurrence survival.

Results

Of patients undergoing LR for ICC, 499 developed recurrence. The median time to recurrence was 10 months, and 47% were intrahepatic. Overall 3-year post-recurrence survival rate was 28.6%. In total, 121 patients (25%) underwent repeat resection, including 74 (61%) repeat LRs. Surgically treated patients were more likely to have solitary intrahepatic recurrences and significantly prolonged survival compared with those receiving locoregional or systemic therapy alone with a 3-year post-recurrence survival rate of 47%. Independent predictors of post-recurrence death included time to recurrence < 1 year [HR 1.66 (1.32–2.10), p < 0.001], site of recurrence [HR 1.74 (1.28–2.38), p < 0.001], macrovascular invasion [HR 1.43 (1.05–1.95), p = 0.024], and size of recurrence > 3 cm [HR 1.68 (1.24–2.29), p = 0.001]. Repeat resection was independently associated with decreased post-recurrence death [HR 0.58 0.43–0.78), p < 0.001].

Conclusions

Repeat resection for recurrent ICC in select patients can result in extended survival. Thus, challenging the paradigm of offering these patients locoregional or chemo/palliative therapy alone as the mainstay of treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma—evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018;15:95.

    Article  CAS  Google Scholar 

  2. Banales JM, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557–88.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma. JAMA Surg. 2014;149:565.

    Article  PubMed  Google Scholar 

  4. de Jong MC, et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol. 2011;29:3140–5.

    Article  PubMed  Google Scholar 

  5. Hu LS, et al. Impact of microvascular invasion on clinical outcomes after curative-intent resection for intrahepatic cholangiocarcinoma. J Surg Oncol. 2019;119:21–9.

    Article  PubMed  Google Scholar 

  6. Hu LS, et al. Recurrence patterns and timing courses following curative-intent resection for intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2019. https://doi.org/10.1245/s10434-019-07353-4.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Primrose JN, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20:663–73.

    Article  CAS  PubMed  Google Scholar 

  8. Bridgewater J, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60:1268–89.

    Article  PubMed  Google Scholar 

  9. Weber SM, et al. Intrahepatic cholangiocarcinoma: expert consensus statement. HPB. 2015;17:669.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Benson AB, et al. Hepatobiliary Cancers, Version 5.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19:541–65.

    Article  PubMed  Google Scholar 

  11. Ercolani G, et al. Intrahepatic cholangiocarcinoma: primary liver resection and aggressive multimodal treatment of recurrence significantly prolong survival. Ann Surg. 2010;252:107–14.

    Article  PubMed  Google Scholar 

  12. Bekki Y, von Ahrens D, Takahashi H, Schwartz M, Gunasekaran G. Recurrent intrahepatic cholangiocarcinoma–review. Front Oncol. 2021;11:776863.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Kitano Y, et al. Effectiveness of surgery for recurrent cholangiocarcinoma: a single center experience and brief literature review. Am J Surg. 2020;219:175–80.

    Article  PubMed  Google Scholar 

  14. Takahashi Y, et al. Surgery for recurrent biliary tract cancer: a single-center experience with 74 consecutive resections. Ann Surg. 2015;262:121–9.

    Article  PubMed  Google Scholar 

  15. Yoh T, et al. Long-term survival of recurrent intrahepatic cholangiocarcinoma: the impact and selection of repeat surgery. World J Surg. 2018;42:1848–56.

    Article  PubMed  Google Scholar 

  16. Si A, et al. Effectiveness of repeat hepatic resection for patients with recurrent intrahepatic cholangiocarcinoma: factors associated with long-term outcomes. Surgery. 2017;161:897–908.

    Article  PubMed  Google Scholar 

  17. Sulpice L, et al. Treatment of recurrent intrahepatic cholangiocarcinoma. BJS. 2012;99:1711–7.

    Article  CAS  Google Scholar 

  18. Spolverato G, et al. Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma following previous curative-intent surgical resection. Ann Surg Oncol. 2016;23:235–43.

    Article  PubMed  Google Scholar 

  19. Park HM, et al. Outcomes for patients with recurrent intrahepatic cholangiocarcinoma after surgery. Ann Surg Oncol. 2016;23:4392–400.

    Article  PubMed  Google Scholar 

  20. Souche R, et al. First and repeat liver resection for primary and recurrent intrahepatic cholangiocarcinoma. Am J Surg. 2016;212:221–9.

    Article  PubMed  Google Scholar 

  21. Bartsch F, et al. Repeated resection for recurrent intrahepatic cholangiocarcinoma: a retrospective German multicentre study. Liver Int. 2021;41:180–91.

    Article  PubMed  Google Scholar 

  22. Zhang SJ, et al. Thermal ablation versus repeated hepatic resection for recurrent intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2013;20:3596–602.

    Article  PubMed  Google Scholar 

  23. Ge Y, et al. Transarterial chemoembolization versus percutaneous microwave coagulation therapy for recurrent unresectable intrahepatic cholangiocarcinoma: development of a prognostic nomogram. HBPD INT. 2020;19:138–46.

    CAS  PubMed  Google Scholar 

  24. Smart AC, et al. Hypofractionated radiation therapy for unresectable/locally recurrent intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2020;27:1122–9.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Contributions

Tabrizian, Schwartz, and Holzner were responsible for the concept and study design; Holzner, Tabrizian, Mazaferro, Brusset, Ratti, Arita, Sapisochin, Abreu, Schoning, Schmelzle, and Nevermann performed data acquisition, analysis, or interpretation; Holzner and Tabrizian drafted the manuscript; Schwartz, Mazzaferro, Aldrighetti, Hasegawa, Pratschke, Sapisochin, and Florman performed critical revision of the manuscript for important intellectual content; Holzner and Tabrizian performed statistical analysis; and Florman, Halazun, and Schwartz supervised the study.

Corresponding author

Correspondence to Parissa Tabrizian MD, MSc.

Ethics declarations

Disclosures

Prof. Moritz Schmelzle has relevant financial activities outside of the submitted work to disclose from Merck Serono GmbH, Bayer AG, ERBE Elektromedizin GmbH, Amgen Inc., AstraZeneca, Avateramedical GmbH, Johnson & Johnson Medical GmbH, Takeda Pharmaceutical Limited, Olympus K.K., Medtronic GmbH, Intuitive Surgical Inc., Corzamedical, and Baxter Int Inc.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Holzner, M.L., Mazzaferro, V., Busset, M.D.D. et al. Is Repeat Resection for Recurrent Intrahepatic Cholangiocarcinoma Warranted? Outcomes of an International Analysis. Ann Surg Oncol 31, 4397–4404 (2024). https://doi.org/10.1245/s10434-024-14975-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-024-14975-w

Keywords

Navigation